|
stroke |
23 |
|
ischemic stroke |
19 |
|
intracerebral hemorrhage |
14 |
|
hypertension |
13 |
|
blood pressure |
11 |
|
mortality |
11 |
|
myocardial infarction |
11 |
|
warfarin |
11 |
|
endothelial function |
9 |
|
garlic |
9 |
|
blood pressure variability |
8 |
|
cardiovascular and cerebrovascular diseases |
8 |
|
prognosis |
8 |
|
type 2 diabetes mellitus |
8 |
|
vascular markers |
8 |
|
vascular markers of atherosclerosis |
8 |
|
als |
7 |
|
antiplatelet medication |
7 |
|
cutoff |
7 |
|
genetics |
7 |
|
hematoma location |
7 |
|
lacunar infarct |
7 |
|
next generation sequencing |
7 |
|
stroke outcome |
7 |
|
survival |
7 |
|
cardiovascular event |
6 |
|
cerebrovascular event |
6 |
|
cognition |
6 |
|
cognitive impairment |
6 |
|
ich volume |
6 |
|
intraventricular extension |
6 |
|
neurological deterioration |
6 |
|
obstructive sleep apnea |
6 |
|
sleep disturbance |
6 |
|
spondyloarthritis |
6 |
|
visit-to-visit blood pressure variability |
6 |
|
warfarin-associated ich |
6 |
|
atrial fibrillation |
5 |
|
cerebral microbleed |
5 |
|
cerebral small vessel disease |
5 |
|
chronic kidney disease |
5 |
|
direct oral anticoagulant |
5 |
|
follow-up |
5 |
|
intracranial hemorrhage |
5 |
|
magnetic |
5 |
|
renal function variability |
5 |
|
renal impairment |
5 |
|
resonance imaging |
5 |
|
secondary prevention |
5 |
|
survivors |
5 |
|
acquired myasthenia gravis |
4 |
|
aquaporin-4 autoantibodies |
4 |
|
autoimmune |
4 |
|
azathioprine |
4 |
|
bronchiectasis |
4 |
|
cardiovascular disease |
4 |
|
carotid initial thickness |
4 |
|
cera |
4 |
|
classical multiple sclerosis |
4 |
|
clinical outcome |
4 |
|
coronavirus disease |
4 |
|
esa |
4 |
|
fatigue |
4 |
|
hospitalization |
4 |
|
immunosuppressant therapy |
4 |
|
inflammatory demyelinating disorders |
4 |
|
interleukin-1beta (il-1β) |
4 |
|
interleukin-8 (il-8) |
4 |
|
low‐density lipoprotein cholesterol |
4 |
|
neuromyelitis optica spectrum disorders |
4 |
|
prospective cohort study |
4 |
|
public health |
4 |
|
renal anemia |
4 |
|
renal palliative care |
4 |
|
sputum cytokines |
4 |
|
subclinical atherosclerosis |
4 |
|
tumor necrosis factor-alpha (tnf-α) |
4 |
|
cardiovascular diseases |
3 |
|
hong kong |
3 |
|
neurodegenerative diseases |
3 |
|
peripheral vascular diseases |
3 |
|
pleiotropy |
3 |
|
covid-19 infection |
2 |
|
covid-19 vaccine |
2 |
|
disease-modification |
2 |
|
epilepsy |
2 |
|
monoamine oxidase-b inhibitors |
2 |
|
neurological adverse effects |
2 |
|
neuroprotection |
2 |
|
parkinson's disease |
2 |
|
rasagiline |
2 |
|
seizure |
2 |
|
selegiline |
2 |
|
vaccination gap |
2 |
|
endovascular thrombectomy |
1 |
|
geriatric |
1 |